This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
I guess we'll get started. I'm Liana Moussatos from Wedbush. Welcome to our Third Annual LS MAC Conference. Right now we have Dr. Arthur Sands, CEO of Lexicon Pharmaceuticals, who'll give us a corporate update. Dr. Sands?
Dr. Arthur Sands
Thank you, Leigh Ann. It's a pleasure to be with you today. I will be making certain forward-looking statements and so I'd like to refer you to our filings with the SEC regarding risk factors that affect our business and our pipeline. So, it's been a very exciting and very busy summer for Lexicon as we've received our data from our LX4211 Phase 2b trial in diabetes. And I'll spend most of the session today describing the data from that trial. But I'll also put in context of our broader development plan for LX4211 as we get ready to move into Phase 3 with that compound.
Now all the compounds of Lexicon derive from our genetics engine. Our mission for those of you who don't know is we're dedicated to developing truly breakthrough therapies for disease that are all targeted in nature that as we use genetics and gene knockout technology to define the target, and so all of our programs are genetically defined as targets. And then we have a medicinal chemistry group that develops small molecules for those targets. So our entire pipeline has been developed within this research engine with genetics at the beginning and then getting to small molecule development.